NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

Novocure Limited (NASDAQ: NVCR ) develops wearables that generate Tumor Treating Fields (TTFields), which can be used for treating aggressive cancers. In that sense, NVCR features approved devices like Optune and Optune Gio for treating glioblastoma (GBM). NVCR’s Optune Lua instead helpsMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athen ...

For the quarter ended June 2025, Penumbra (PEN) reported revenue of $339.46 million, up 13.4% over the same period last year. EPS came in at $0.86, compared to $0.64 in the year-ago quarter.The reported revenue represents a surprise of +3.54% over the Zacks Consensus Estimate of $327.85 million. With the consensus EPS estimate being $0.81, the EPS surprise was +6.17%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

财务数据和关键指标变化 - 2025年第二季度净销售额为2320万美元 同比增长54% [13] - 毛利率为53.8% 较2024年同期53.7%略有提升 [15] - 运营费用3240万美元 同比增长63% [27] - 截至2025年6月30日 现金及等价物为2.81亿美元 [28] - 2025年全年收入指引上调至8800-9300万美元 [30] 各条业务线数据和关键指标变化 - 第二季度新增4934名Islet用户 同比增长57% [14] - 约71%新用户来自每日多次注射治疗的患者 [21] - 通过药房渠道报销的新用户占比达20%以上 显著高于去年同期的个位数百分比 [14] - 药房安装基础规模是2024年的7倍以上 [24] 各个市场数据和关键指标变化 - 10-15%用户为传统Medicare按服务收费受益人 [36] - 药房渠道扩张取得进展 已与所有主要PBM达成有效处方协议 [14] - Prime Therapeutics合作协议自2月1日生效后带来显著拉动效应 [32] 公司战略和发展方向和行业竞争 - 强调Islet系统在自动化程度和临床结果上的行业领先优势 [10] - 推出Mint贴片泵计划 目标2027年商业化 [47] - 双激素泵项目取得进展 已完成PKPD桥接研究 [47] - 扩大销售团队至63个区域 [19] - 应对CMS提出的2026年DME支付系统改革方案 [36] 管理层对经营环境和未来前景的评论 - 预计第三季度收入略高于第二季度 第四季度将季节性增长 [31] - 药房渠道在中期和长期将带来更高毛利率 [25] - 预计2025年下半年药房占比将继续上升但增速放缓 [32] - 关税影响预计有限 关键组件享受内罗毕协议豁免 [35] 其他重要信息 - 超过25%新用户为2型糖尿病患者 [50] - 推出Bionic Portal医疗门户更新 提供实时临床结果 [18] - 2024年推出的三项新产品持续获得市场认可 [19] 问答环节所有的提问和回答 关于药房渠道定价 - 药房ASP下降源于PBM采用率提高导致的返利增加 [58] - 第二季度药房供应套件库存动态影响表现 [59] 关于用户流失率 - 公司未披露具体流失率数据 但强调药房渠道留存表现良好 [61] - 优先将符合条件的用户引导至药房渠道 [63] 关于CMS提案 - 预计最早2027年实施竞标和租赁模式 [75] - 新模式可能为新进入者创造优势 [43] - 不认为提案会影响商业DME或Medicare Advantage合同 [85] 关于销售团队扩张 - 2025年初销售区域从43个增至63个 [104] - 预计2025年剩余时间不会大幅增加区域 [104] 关于研发支出 - 预计2025年下半年研发费用将因Mint和双激素项目增加 [133] - 未来季度研发支出可能呈现波动 [134]

AtriCure (ATRC) Q2 2025 Earnings Call July 29, 2025 04:30 PM ET Speaker0Good afternoon, and welcome to AtriCure's Second Quarter twenty twenty five Earnings Conference Call. This call is being recorded for replay purposes. And at this time, all participants are in listen only mode. We will be facilitating a question and answer session following the prepared remarks by AtriCure's management. I would now like to turn the call over to Marissa Beisch from the Gilmartin Group for a few introductory comments.Spea ...

Penumbra (PEN) Q2 2025 Earnings Call July 29, 2025 04:30 PM ET Speaker0Ladies and gentlemen, good afternoon. My name is Abby, and I'll be your conference operator today. At this time, I would like to welcome everyone to Penumbra's Second Quarter twenty twenty five Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session.If you would like to ask a question during that time, simply press star followed by the n ...

公司概况 - RxSight是一家位于加州Aliso Viejo的医疗技术公司 专注于开发用于白内障手术的光可调节人工晶体(LAL) 其核心产品为RxSight系统中的光传输设备(LDD) [2] 诉讼核心指控 - 公司被指控在2024年11月7日至2025年7月8日期间未向投资者披露：1) 产品面临"采用挑战"和结构性销售下滑问题 2) 夸大产品需求 3) 无法实现2025财年既定财务目标 [3] - 2025年7月8日公司公告显示：LDD设备销量 LAL使用率和整体收入在2025年第二季度显著下降 同时下调2025全年收入指引 [4] - CEO Ronald Kurtz承认"过去几个季度的采用挑战是LDD销售停滞的主要原因" [4] 市场反应 - 负面公告导致次日(2025年7月9日)股价单日暴跌4.84美元(37%) 收盘价报7.95美元/股 [4] 法律程序 - 集体诉讼代表资格申请截止日为2025年9月22日 涵盖2024年11月7日至2025年7月8日期间购入公司证券的投资者 [1][2]

SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: http ...

AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025 July 29, 2025 MASON, Ohio--(BUSINESS WIRE)--Jul. 29, 2025-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2025 financial results. "Our stellar results reflect the power of innovation and the growing impact of our expanding portfolio, particul ...

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Monday, August 18, 2025. Company management will host a conference call to disc ...